Association of Toll-Like Receptor 3 Single-Nucleotide Polymorphisms and Hepatitis C Virus Infection

Table 3

Genotypic distribution of TLR3 gene polymorphisms when all HCV-infected patients were compared to healthy control group.

SNPs	Genotype/allele distribution	Healthy controls	HCV patients	OR (95% CI)		value
		rs5743311	AA				1 (0.17%)	0 (0%)	0.360 (0.015–8.846)	0.93	0.336
AG	10 (1.67%)		18 (3.2%)	1.942 (0.889–4.244)	2.87	0.091
GG	588 (98.16%)		545 (96.8%)	Ref
A	12 (1%)		18 (1.6%)	1.606 (0.770–3.348)	1.62	0.203
G	1186 (99%)		1108 (98.4%)
AA+AG.VS.GG				1.765 (0.826–3.772)	2.21	0.137
AA.VS.AG+GG				2.825 (0.115–69.479)	0.94	0.332
rs5743312	TT	18 (3.01%)	16 (2.84%)	0.959 (0.482–1.905)	0.01	0.903
	CT	141 (23.54%)	139 (24.69%)	1.063 (0.811–1.393)	0.2	0.657
	CC	440 (73.46%)	408 (72.47%)	Ref
	T	177 (14.77%)	171 (15.19%)	1.033 (0.822–1.297)	0.08	0.781
	C	1021 (85.23%)	955 (84.81%)
	TT+CT.VS.CC			1.051 (0.811–1.362)	0.14	0.705
	TT.VS.CT+CC			1.059 (0.535–2.098)	0.03	0.869
rs1879026	TT	23 (3.84%)	15 (2.66%)	0.701 (0.361–1.363)	1.11	0.292
	GT	160 (26.71%)	161 (28.6%)	1.082 (0.835–1.401)	0.35	0.552
	GG	416 (69.45%)	387 (68.74%)	Ref
	T	206 (17.2%)	191 (16.96%)	0.984 (0.792–1.221)	0.02	0.882
	G	992 (82.8%)	935 (83.04%)
	TT+GT.VS.GG			1.034 (0.806–1.326)	0.07	0.793
	TT.VS.GT+GG			1.459 (0.753–2.825)	1.27	0.2602
rs5743313	TT	42 (7.01%)	37 (6.57%)	0.952 (0.595–1.524)	0.04	0.838
	CT	250 (41.74%)	242 (42.98%)	1.046 (0.824–1.329)	0.14	0.71
	CC	307 (51.25%)	284 (50.44%)	Ref
	T	334 (27.88%)	316 (28.06%)	1.009 (0.842–1.210)	0.01	0.921
	C	864 (72.12%)	810 (71.94%)
	TT+CT.VS.CC			1.033 (0.821–1.300)	0.08	0.783
	TT.VS.CT+CC			1.072 (0.678–1.694)	0.09	0.766
rs5743314	CC	44 (7.35%)	37 (6.57%)	0.897 (0.563–1.429)	0.21	0.646
	GC	249 (41.57%)	239 (42.45%)	1.023 (0.805–1.301)	0.04	0.8501
	GG	306 (51.09%)	287 (50.98%)	Ref
	C	337 (28.13%)	313 (27.8%)	0.984 (0.821–1.179)	0.03	0.858
	G	861 (71.87%)	813 (72.2%)
	CC+GC.VS.GG			1.004 (0.798–1.264)	0	0.971
	CC.VS.GC+GG			1.127 (0.716–1.773)	0.27	0.605
rs5743315	AA	9 (1.5%)	3 (0.53%)	0.352 (0.095–1.309)	2.65	0.104
	AC	123 (20.53%)	118 (20.96%)	1.014 (0.763–1.347)	0.01	0.926
	CC	467 (77.96%)	442 (78.51%)	Ref
	A	141 (11.77%)	124 (11.01%)	0.928 (0.718–1.199)	0.33	0.566
	C	1057 (88.23%)	1002 (88.99%)
	AA+AC.VS.CC			0.969 (0.733–1.280)	0.05	0.822
	AA.VS.AC+CC			2.847 (0.767–10.572)	2.67	0.102
rs111611328	CC	3 (0.5%)	1 (0.18%)	0.353 (0.037–3.404)	0.89	0.346
	GC	6 (1%)	5 (0.89%)	0.883 (0.268–2.909)	0.04	0.837
	GG	590 (98.5%)	557 (98.93%)	Ref
	C	12 (1%)	7 (0.62%)	0.618 (0.243–1.576)	1.03	0.309
	G	1186 (99%)	1119 (99.38%)
	CC+GC.VS.GG			0.706 (0.250–1.997)	0.43	0.509
	CC.VS.GC+GG			2.829 (0.293–27.275)	0.88	0.347
rs78726532	GG	12 (2%)	3 (0.53%)	0.264 (0.074–0.942)	4.84	0.027
	AG	120 (20.03%)	118 (20.96%)	1.039 (0.781–1.382)	0.07	0.793
	AA	467 (77.96%)	442 (78.51%)	Ref
	G	144 (12.02%)	124 (11.01%)	0.906 (0.702–1.169)	0.58	0.447
	A	1054 (87.98%)	1002 (88.99%)
	GG+AG.VS.AA			0.969 (0.733–1.280)	0.05	0.822
	GG.VS.AG+AA			3.816 (1.071–13.594)	4.92	0.026

Note: risk alleles are marked in bold letters.